Cwm LLC Has $781,000 Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Cwm LLC raised its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 363.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,106 shares of the biotechnology company’s stock after purchasing an additional 8,708 shares during the period. Cwm LLC’s holdings in BioMarin Pharmaceutical were worth $781,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of BMRN. Principal Financial Group Inc. boosted its holdings in BioMarin Pharmaceutical by 1,858.6% in the 2nd quarter. Principal Financial Group Inc. now owns 649,460 shares of the biotechnology company’s stock valued at $53,470,000 after purchasing an additional 616,301 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of BioMarin Pharmaceutical by 11,107.4% during the 2nd quarter. Assenagon Asset Management S.A. now owns 352,474 shares of the biotechnology company’s stock worth $29,019,000 after acquiring an additional 349,329 shares during the period. Rhumbline Advisers lifted its holdings in shares of BioMarin Pharmaceutical by 122.1% during the 2nd quarter. Rhumbline Advisers now owns 551,553 shares of the biotechnology company’s stock worth $45,409,000 after acquiring an additional 303,207 shares during the period. Swedbank AB bought a new position in shares of BioMarin Pharmaceutical during the 1st quarter worth about $25,864,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of BioMarin Pharmaceutical by 38.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,034,457 shares of the biotechnology company’s stock worth $85,178,000 after acquiring an additional 289,953 shares during the period. 98.71% of the stock is owned by institutional investors.

BioMarin Pharmaceutical Trading Up 0.9 %

BMRN opened at $70.11 on Friday. The company has a current ratio of 3.05, a quick ratio of 1.95 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $13.31 billion, a PE ratio of 65.52, a PEG ratio of 0.81 and a beta of 0.31. BioMarin Pharmaceutical Inc. has a 1-year low of $67.75 and a 1-year high of $99.56. The firm has a 50-day moving average price of $79.48 and a two-hundred day moving average price of $82.05.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Monday, August 5th. The biotechnology company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.39. The firm had revenue of $712.03 million during the quarter, compared to analysts’ expectations of $660.51 million. BioMarin Pharmaceutical had a net margin of 9.91% and a return on equity of 6.91%. As a group, equities analysts anticipate that BioMarin Pharmaceutical Inc. will post 2.39 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on BMRN. William Blair raised shares of BioMarin Pharmaceutical to a “strong-buy” rating in a report on Friday, August 30th. StockNews.com raised shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. JPMorgan Chase & Co. raised their price objective on shares of BioMarin Pharmaceutical from $111.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday, September 5th. Barclays reduced their price objective on shares of BioMarin Pharmaceutical from $110.00 to $86.00 and set an “overweight” rating for the company in a report on Friday, October 4th. Finally, Bank of America dropped their target price on shares of BioMarin Pharmaceutical from $130.00 to $115.00 and set a “buy” rating for the company in a research report on Tuesday, September 17th. Seven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $96.40.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.